Bone marrow–derived mesenchymal stem cells transduced with scleraxis improve rotator cuff healing in a rat model
LV Gulotta, D Kovacevic, JD Packer… - … American journal of …, 2011 - journals.sagepub.com
The American journal of sports medicine, 2011•journals.sagepub.com
Background: Rotator cuffs heal through a scar tissue interface after repair that makes them
prone to failure. Scleraxis (Scx) is a basic helix-loop-helix transcription factor that is thought
to direct tendon development during embryogenesis. The purpose of this study was to
determine if the application of mesenchymal stem cells (MSCs) transduced with adenoviral-
mediated scleraxis (Ad-Scx) could improve regeneration of the tendon-bone insertion site in
a rat rotator cuff repair model. Hypothesis: Bone marrow–derived cells transduced with Scx …
prone to failure. Scleraxis (Scx) is a basic helix-loop-helix transcription factor that is thought
to direct tendon development during embryogenesis. The purpose of this study was to
determine if the application of mesenchymal stem cells (MSCs) transduced with adenoviral-
mediated scleraxis (Ad-Scx) could improve regeneration of the tendon-bone insertion site in
a rat rotator cuff repair model. Hypothesis: Bone marrow–derived cells transduced with Scx …
Background: Rotator cuffs heal through a scar tissue interface after repair that makes them prone to failure. Scleraxis (Scx) is a basic helix-loop-helix transcription factor that is thought to direct tendon development during embryogenesis. The purpose of this study was to determine if the application of mesenchymal stem cells (MSCs) transduced with adenoviral-mediated scleraxis (Ad-Scx) could improve regeneration of the tendon-bone insertion site in a rat rotator cuff repair model.
Hypothesis: Bone marrow–derived cells transduced with Scx would improve the structure of the healing tendon-bone interface and result in increased tendon attachment strength.
Study Design: Controlled laboratory study.
Methods: Sixty Lewis rats underwent unilateral detachment and repair of the supraspinatus tendon. Thirty animals received MSCs in a fibrin glue carrier, and 30 received Ad-Scx-transduced MSCs. Animals were sacrificed at 2 weeks and 4 weeks and evaluated for the presence of fibrocartilage and collagen fiber organization at the insertion. Biomechanical testing was performed to determine the structural and material properties of the repaired tissue. Statistical analysis was performed with a Wilcoxon rank sum test with significance set at P = .05.
Results: There were no differences between the Scx and MSC groups in terms of histologic appearance at 2 weeks. However, the Scx group had higher ultimate stress-to-failure (2.6 ± 0.9 vs 1.7 ± 0.3 MPa; P = .03) and stiffness (8.4 ± 2.9 vs 5.0 ± 1.9 N/mm; P = .01) compared with the MSC group. At 4 weeks, the Scx group had more fibrocartilage (728.7 ± 50.4 vs 342.6 ± 217.0 mm2; P = .04), higher ultimate load to failure (26.7 ± 4.6 vs 20.8 ± 4.4 N; P = .01), higher ultimate stress to failure (4.7 ± 1.3 vs 3.5 ± 1.0 MPa; P < .04), and higher stiffness values (15.3 ± 3.4 vs 9.3 ± 2.2 N/mm; P < .001) as compared with the MSC group.
Conclusion: Mesenchymal stem cells genetically modified with Scx can augment rotator cuff healing at early time points.
Clinical Relevance: Biologic augmentation of acutely injured rotator cuffs with Scx-transduced MSCs may improve rotator cuff tendon healing and reduce the incidence of re-tears. However, further studies are needed to determine if this remains safe and effective in larger models.
Sage Journals